The VHL tumor suppressor in development and disease: Functional studies in mice by conditional gene targeting

Seminars in Cell and Developmental Biology

Volumn 16, Issue 4-5, 2005, Pages 564-574

  Haase, Volker H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Conditional knock out mice; Hemangioma; Hypoxia inducible factor (HIF); Renal cell cancer; Von Hippel Lindau (VHL) tumor suppressor

Indexed keywords

CRE RECOMBINASE; HYPOXIA INDUCIBLE FACTOR 1; TUMOR SUPPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; CANCER GENETICS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; DISEASE PREDISPOSITION; EMBRYO DEVELOPMENT; GENE TARGETING; HYPOXIA; KIDNEY CARCINOMA; KNOCKOUT MOUSE; LOXP SITE; MOUSE; NONHUMAN; PHENOTYPE; PHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VASCULAR TUMOR;

EID: 24344452947     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2005.03.006     Document Type: Review

References (123)

1. Maher ER, Kaelin WG, Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997; 76:381-91.
2. J.R. Gnarra, K. Tory, Y. Weng, L. Schmidt, M.H. Wei, and H. Li Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
3. O. Iliopoulos, A. Kibel, S. Gray, and W.G. Kaelin Jr. Tumour suppression by the human von Hippel-Lindau gene product Nat Med 1 1995 822 826
4. J.R. Gnarra, S. Zhou, M.J. Merrill, J.R. Wagner, A. Krumm, and E. Papavassiliou Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene Proc Natl Acad Sci USA 93 1996 10589 10594
5. A. Schoenfeld, E.J. Davidowitz, and R.D. Burk A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor Proc Natl Acad Sci USA 95 1998 8817 8822
6. F. Latif, K. Tory, J. Gnarra, M. Yao, F.M. Duh, and M.L. Orcutt Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320
7. O. Iliopoulos, A.P. Levy, C. Jiang, W.G. Kaelin Jr., and M.A. Goldberg Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proc Natl Acad Sci USA 93 1996 10595 10599
8. G. Siemeister, K. Weindel, K. Mohrs, B. Barleon, G. Martiny-Baron, and D. Marme Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein Cancer Res 56 1996 2299 2301
9. D.R. Duan, A. Pause, W.H. Burgess, T. Aso, D.Y. Chen, and K.P. Garrett Inhibition of transcription elongation by the VHL tumor suppressor protein [see comments] Science 269 1995 1402 1406
10. A. Kibel, O. Iliopoulos, J.A. DeCaprio, and W.G. Kaelin Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C [see comments] Science 269 1995 1444 1446
11. A. Pause, S. Lee, R.A. Worrell, D.Y. Chen, W.H. Burgess, and W.M. Linehan The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins Proc Natl Acad Sci USA 94 1997 2156 2161
12. T. Kamura, D.M. Koepp, M.N. Conrad, D. Skowyra, R.J. Moreland, and O. Iliopoulos Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase [see comments] Science 284 1999 657 661
13. C.E. Stebbins, W.G. Kaelin Jr., and N.P. Pavletich Structure of the VHL-elongin C-elongin B complex: implications for VHL tumor suppressor function Science 284 1999 455 461
14. D.E. Feldman, V. Thulasiraman, R.G. Ferreyra, and J. Frydman Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC Mol Cell 4 1999 1051 1061
15. K. Iwai, K. Yamanaka, T. Kamura, N. Minato, R.C. Conaway, and J.W. Conaway Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex Proc Natl Acad Sci USA 96 1999 12436 12441
16. J. Lisztwan, G. Imbert, C. Wirbelauer, M. Gstaiger, and W. Krek The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity Genes Dev 13 1999 1822 1833
17. P.H. Maxwell, M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, and M.E. Cockman The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments] Nature 399 1999 271 275
18. S. Salceda, and J. Caro Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes J Biol Chem 272 1997 22642 22647
19. M.E. Cockman, N. Masson, D.R. Mole, P. Jaakkola, G.W. Chang, and S.C. Clifford Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J Biol Chem 275 2000 25733 25741
20. K. Tanimoto, Y. Makino, T. Pereira, and L. Poellinger Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein EMBO J 19 2000 4298 4309
21. M. Ohh, C.W. Park, M. Ivan, M.A. Hoffman, T.Y. Kim, and L.E. Huang Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat Cell Biol 2 2000 423 427
22. T. Kamura, S. Sato, K. Iwai, M. Czyzyk-Krzeska, R.C. Conaway, and J.W. Conaway Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex Proc Natl Acad Sci USA 97 2000 10430 10435
23. G.L. Semenza HIF-1 and mechanisms of hypoxia sensing Curr Opin Cell Biol 13 2001 167 171
24. 2-regulated gene expression FASEB J 16 2002 1151 1162
25. R.J. Kewley, M.L. Whitelaw, and A. Chapman-Smith The mammalian basic helix-loop-helix/PAS family of transcriptional regulators Int J Biochem Cell Biol 36 2004 189 204
26. D.M. Stroka, T. Burkhardt, I. Desbaillets, R.H. Wenger, D.A. Neil, and C. Bauer HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia FASEB J 15 2001 2445 2453
27. T. Kietzmann, Y. Cornesse, K. Brechtel, S. Modaressi, and K. Jungermann Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver Biochem J 354 2001 531 537
28. M.S. Wiesener, J.S. Jurgensen, C. Rosenberger, C.K. Scholze, J.H. Horstrup, and C. Warnecke Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs FASEB J 17 2003 271 273
29. V. Compernolle, K. Brusselmans, T. Acker, P. Hoet, M. Tjwa, and H. Beck Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice Nat Med 8 2002 702 710
30. M.A. Maynard, H. Qi, J. Chung, E.H. Lee, Y. Kondo, and S. Hara Multiple splice variants of the human HIF-3alpha locus are targets of the VHL E3 ubiquitin ligase complex J Biol Chem 21 2003 21
31. 2-regulated prolyl hydroxylation Science 292 2001 468 472
32. 2 sensing Science 292 2001 464 468
33. A.C. Epstein, J.M. Gleadle, L.A. McNeill, K.S. Hewitson, J. O'Rourke, and D.R. Mole C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 2001 43 54
34. W.C. Hon, M.I. Wilson, K. Harlos, T.D. Claridge, C.J. Schofield, and C.W. Pugh Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL Nature 417 2002 975 978
35. N. Masson, C. Willam, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation EMBO J 20 2001 5197 5206
36. F. Yu, S.B. White, Q. Zhao, and F.S. Lee HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation Proc Natl Acad Sci USA 98 2001 9630 9635
37. R.K. Bruick, and S.L. McKnight A conserved family of prolyl-4- hydroxylases that modify HIF Science 294 2001 1337 1340
38. P.C. Mahon, K. Hirota, and G.L. Semenza FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev 15 2001 2675 2686
39. D. Lando, D.J. Peet, J.J. Gorman, D.A. Whelan, M.L. Whitelaw, and R.K. Bruick FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor Genes Dev 16 2002 1466 1471
40. J.L. Da Silva, C. Lacombe, P. Bruneval, N. Casadevall, M. Leporrier, and J.P. Camilleri Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia Blood 75 1990 577 582
41. M. Krieg, H.H. Marti, and K.H. Plate Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function Blood 92 1998 3388 3393
42. S.O. Ang, H. Chen, K. Hirota, V.R. Gordeuk, J. Jelinek, and Y. Guan Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia Nat Genet 32 2002 614 621
43. V.R. Gordeuk, A.I. Sergueeva, G.Y. Miasnikova, D. Okhotin, Y. Voloshin, and P.L. Choyke Congenital disorder of oxygen sensing: association of the homozygous. Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors Blood 103 2004 3924 3932
44. M.A. Hoffman, M. Ohh, H. Yang, J.M. Klco, M. Ivan, and W.G. Kaelin Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum Mol Genet 10 2001 1019 1027
45. S.C. Clifford, M.E. Cockman, A.C. Smallwood, D.R. Mole, E.R. Woodward, and P.H. Maxwell Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease Hum Mol Genet 10 2001 1029 1038
46. M. Ohh, R.L. Yauch, K.M. Lonergan, J.M. Whaley, A.O. Stemmer-Rachamimov, and D.N. Louis The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol Cell 1 1998 959 968
47. S. Koochekpour, M. Jeffers, P.H. Wang, C. Gong, G.A. Taylor, and L.M. Roessler The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells Mol Cell Biol 19 1999 5902 5912
48. E.J. Davidowitz, A.R. Schoenfeld, and R.D. Burk VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling Mol Cell Biol 21 2001 865 874
49. T. Bishop, K.W. Lau, A.C. Epstein, S.K. Kim, M. Jiang, and D. O'Rourke Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans PLoS Biol 2 2004 e289
50. A. Hergovich, J. Lisztwan, R. Barry, P. Ballschmieter, and W. Krek Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL Nat Cell Biol 5 2003 64 70
51. M.I. Zhou, H. Wang, R.L. Foy, J.J. Ross, and H.T. Cohen Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent Cancer Res 64 2004 1278 1286
52. M.I. Zhou, H. Wang, J.J. Ross, I. Kuzmin, C. Xu, and H.T. Cohen The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1 J Biol Chem 277 2002 39887 39898
53. S. Pal, K.P. Claffey, H.F. Dvorak, and D. Mukhopadhyay The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways J Biol Chem 272 1997 27509 27512
54. S. Pal, K.P. Claffey, H.T. Cohen, and D. Mukhopadhyay Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta J Biol Chem 273 1998 26277 26280
55. K. Datta, R. Nambudripad, S. Pal, M. Zhou, H.T. Cohen, and D. Mukhopadhyay Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer J Biol Chem 275 2000 20700 20706
56. K. Datta, C. Sundberg, S.A. Karumanchi, and D. Mukhopadhyay The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion Cancer Res 61 2001 1768 1775
57. H. Okuda, K. Saitoh, S. Hirai, K. Iwai, Y. Takaki, and M. Baba The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C J Biol Chem 276 2001 43611 43617
58. D. Mukhopadhyay, B. Knebelmann, H.T. Cohen, S. Ananth, and V.P. Sukhatme The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity Mol Cell Biol 17 1997 5629 5639
59. Z. Li, D. Wang, X. Na, S.R. Schoen, E.M. Messing, and G. Wu The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity EMBO J 22 2003 1857 1867
60. Z. Li, X. Na, D. Wang, S.R. Schoen, E.M. Messing, and G. Wu Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein J Biol Chem 277 2002 4656 4662
61. A.V. Kuznetsova, J. Meller, P.O. Schnell, J.A. Nash, M.L. Ignacak, and Y. Sanchez von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination Proc Natl Acad Sci USA 100 2003 2706 2711
62. P.A. Pioli, and W.F. Rigby The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression J Biol Chem 276 2001 40346 40352
63. J.R. Gnarra, J.M. Ward, F.D. Porter, J.R. Wagner, D.E. Devor, and A. Grinberg Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice Proc Natl Acad Sci USA 94 1997 9102 9107
64. V.H. Haase, J.N. Glickman, M. Socolovsky, and R. Jaenisch Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor Proc Natl Acad Sci USA 98 2001 1583 1588
65. A.M. Rojiani, D.A. Owen, K. Berry, B. Woodhurst, F.H. Anderson, and C.H. Scudamore Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease Am J Surg Pathol 15 1991 81 86
66. F.P. McGrath, R.G. Gibney, D.C. Morris, D.A. Owen, and S.R. Erb Case report: multiple hepatic and pulmonary haemangioblastomas - a new manifestation of von Hippel-Lindau disease Clin Radiol 45 1992 37 39
67. W. Ma, L. Tessarollo, S.B. Hong, M. Baba, E. Southon, and T.C. Back Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene Cancer Res 63 2003 5320 5328
68. A.O. Vortmeyer, J.R. Gnarra, M.R. Emmert-Buck, D. Katz, W.M. Linehan, and E.H. Oldfield von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease Hum Pathol 28 1997 540 543
69. B. Lach, A. Gregor, P. Rippstein, and A. Omulecka Angiogenic histogenesis of stromal cells in hemangioblastoma: ultrastructural and immunohistochemical study Ultrastruct Pathol 23 1999 299 310
70. A.O. Vortmeyer, S. Frank, S.Y. Jeong, K. Yuan, B. Ikejiri, and Y.S. Lee Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease Cancer Res 63 2003 7051 7055
71. E. Kleymenova, J.I. Everitt, L. Pluta, M. Portis, J.R. Gnarra, and C.L. Walker Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knock out mice Carcinogenesis 25 2004 309 315
72. H. Gu, J.D. Marth, P.C. Orban, H. Mossmann, and K. Rajewsky Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting Science 265 1994 103 106
73. J.Z. Tsien, D.F. Chen, D. Gerber, C. Tom, E.H. Mercer, and D.J. Anderson Subregion- and cell type-restricted gene knock out in mouse brain Cell 87 1996 1317 1326
74. B. Sauer, and N. Henderson Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1 Proc Natl Acad Sci USA 85 1988 5166 5170
75. M.P. Biju, A.K. Neumann, S.J. Bensinger, R.S. Johnson, L.A. Turka, and V.H. Haase Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes Mol Cell Biol 24 2004 9038 9047
76. E.B. Rankin, D.F. Higgins, J.A. Walisser, R.S. Johnson, C.A. Bradfield, and V.H. Haase Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease associated vascular tumors in mice Mol Cell Biol 25 2005 3163 3172
77. J. Karhausen, G.T. Furuta, J.E. Tomaszewski, R.S. Johnson, S.P. Colgan, and V.H. Haase Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis J Clin Invest 114 2004 1098 1106
78. D. Pfander, T. Kobayashi, M.C. Knight, E. Zelzer, D.A. Chan, and B.R. Olsen Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development Development 131 2004 2497 2508
79. T. Cramer, Y. Yamanishi, B.E. Clausen, I. Forster, R. Pawlinski, and N. Mackman HIF-1alpha is essential for myeloid cell-mediated inflammation Cell 112 2003 645 657
80. Boutin A, Haase VH, Johnson RS. Response to oxygenation in differentiation, function and pathology of the epidermis. In: Biology of hypoxia: the role of oxygen sensing in development, normal function and disease, Keystone Symposia. Colorado: Steamboat Springs; 2004. p. 114.
81. Seagroves TN, Liao D, Cardiff R, Haase VH, Johnson RS. Deletion of vhl impairs normal mammary gland development. In: Biology of hypoxia: the role of oxygen sensing in development, normal function and disease, Keystone Symposia. Colorado: Steamboat Springs; 2004. p. 100.
82. E. Schipani, H.E. Ryan, S. Didrickson, T. Kobayashi, M. Knight, and R.S. Johnson Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival Genes Dev 15 2001 2865 2876
83. W.G. Kaelin Jr. Molecular basis of the VHL hereditary cancer syndrome Nat Rev Cancer 2 2002 673 682
84. A.R. Schoenfeld, T. Parris, A. Eisenberger, E.J. Davidowitz, M. De Leon, and F. Talasazan The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis Oncogene 19 2000 5851 5857
85. P. Devarajan, M. De Leon, F. Talasazan, A.R. Schoenfeld, E.J. Davidowitz, and R.D. Burk The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways J Biol Chem 20 2001 20
86. C.M. Sorenson, B.J. Padanilam, and M.R. Hammerman Abnormal postpartum renal development and cystogenesis in the bcl-2(-/-) mouse Am J Physiol 271 1996 F184 F193
87. F.A. Mack, W.K. Rathmell, A.M. Arsham, J. Gnarra, B. Keith, and M.C. Simon Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth Cancer Cell 3 2003 75 88
88. P.M. Kessler, S.P. Vasavada, R.R. Rackley, T. Stackhouse, F.M. Duh, and F. Latif Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis Mol Med 1 1995 457 466
89. M. Los, G.H. Jansen, W.G. Kaelin, C.J. Lips, G.H. Blijham, and E.E. Voest Expression pattern of the von Hippel-Lindau protein in human tissues Lab Invest 75 1996 231 238
90. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat Rev Cancer 2 2002 38 47
91. K.J. Turner, J.W. Moore, A. Jones, C.F. Taylor, D. Cuthbert-Heavens, and C. Han Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation Cancer Res 62 2002 2957 2961
92. K. Kondo, J.M. Klco, E. Nakamura, M. Lechpammer, and W.G. Kaelin Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 2002 237 246
93. J.K. Maranchi, J.R. Vasselli, J. Riss, J.S. Bonifacio, W.M. Linehan, and R.D. Klausner The contribution of VHL subtrate binding and HIF-1a to the phenotype of vhl loss in renal cell carcinoma Cancer Cell 1 2002 247 253
94. M. Zimmer, D. Doucette, N. Siddiqui, and O. Iliopoulos Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors Mol Cancer Res 2 2004 89 95
95. K. Kondo, W.Y. Kim, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth PLoS Biol 1 2003 E83
96. L. Gunaratnam, M. Morley, A. Franovic, N. de Paulsen, K. Mekhail, and D.A. Parolin Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells J Biol Chem 278 2003 44966 44974
97. N. de Paulsen, A. Brychzy, M.C. Fournier, R.D. Klausner, J.R. Gnarra, and A. Pause Role of transforming growth factor-alpha in von Hippel - Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis Proc Natl Acad Sci USA 98 2001 1387 1392
98. Gunaratnam L, Morley M, Smith K, Lee S. Mechanisms of Hif-2a-dependent tumorigensesis. In: Biology of hypoxia: the role of oxygen sensing in development, normal function and disease, Keystone Symposia. Colorado: Steamboat Springs; 2004. p. 78.
99. D.A. Lowden, G.W. Lindemann, G. Merlino, B.D. Barash, J.P. Calvet, and V.H. Gattone 2nd Renal cysts in transgenic mice expressing transforming growth factor-alpha J Lab Clin Med 124 1994 386 394
100. P. Staller, J. Sulitkova, J. Lisztwan, H. Moch, E.J. Oakeley, and W. Krek Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 425 2003 307 311
101. C. Westenfelder, and R.L. Baranowski Erythropoietin stimulates proliferation of human renal carcinoma cells Kidney Int 58 2000 647 657
102. C. Westenfelder Unexpected renal actions of erythropoietin Exp Nephrol 10 2002 294 298
103. C. Warnecke, Z. Zaborowska, J. Kurreck, V.A. Erdmann, U. Frei, and M. Wiesener Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells FASEB J 18 2004 1462 1464
104. M. Koshiji, Y. Kageyama, E.A. Pete, I. Horikawa, J.C. Barrett, and L.E. Huang HIF-1alpha induces cell cycle arrest by functionally counteracting Myc EMBO J 23 2004 1949 1956
105. P. Carmeliet, Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, and M. Dewerchin Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Nature 394 1998 485 490
106. W.K. Rathmell, M.M. Hickey, N.A. Bezman, C.A. Chmielecki, N.C. Carraway, and M.C. Simon In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations Cancer Res 64 2004 8595 8603
107. H.P. Neumann, and B. Zbar Renal cysts, renal cancer and von Hippel-Lindau disease [editorial] Kidney Int 51 1997 16 26
108. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
109. P. Soriano Generalized lacZ expression with the ROSA26 Cre reporter strain Nat Genet 21 1999 70 71
110. C. Cohen, P.A. McCue, and P.B. Derose Histogenesis of renal cell carcinoma and renal oncocytoma. An immunohistochemical study Cancer 62 1988 1946 1951
111. M.D. Hughson, L.D. Johnson, F.G. Silva, and G. Kovacs Nonpapillary and papillary renal cell carcinoma: a cytogenetic and phenotypic study Mod Pathol 6 1993 449 456
112. D. Droz, D. Zachar, L. Charbit, J. Gogusev, Y. Chretein, and L. Iris Expression of the human nephron differentiation molecules in renal cell carcinomas Am J Pathol 137 1990 895 905
113. W. Ulrich, R. Horvat, and K. Krisch Lectin histochemistry of kidney tumours and its pathomorphological relevance Histopathology 9 1985 1037 1050
114. S.J. Mandriota, K.J. Turner, D.R. Davies, P.G. Murray, N.V. Morgan, and H.M. Sowter HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron Cancer Cell 1 2002 459 468
115. F. Serafini-Cessi, N. Malagolini, and D. Cavallone Tamm-Horsfall glycoprotein: biology and clinical relevance Am J Kidney Dis 42 2003 658 676
116. R.K. Bruick Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia Proc Natl Acad Sci USA 97 2000 9082 9087
117. H.M. Sowter, P.J. Ratcliffe, P. Watson, A.H. Greenberg, and A.L. Harris HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors Cancer Res 61 2001 6669 6673
118. C. Vande Velde, J. Cizeau, D. Dubik, J. Alimonti, T. Brown, and S. Israels BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore Mol Cell Biol 20 2000 5454 5468
119. R.S. Bindra, J.R. Vasselli, R. Stearman, W.M. Linehan, and R.D. Klausner VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells Cancer Res 62 2002 3014 3019
120. M. Zatyka, N.F. da Silva, S.C. Clifford, M.R. Morris, M.S. Wiesener, and K.U. Eckardt Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease Cancer Res 62 2002 3803 3811
121. M. Baba, S. Hirai, H. Yamada-Okabe, K. Hamada, H. Tabuchi, and K. Kobayashi Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor Oncogene 22 2003 2728 2738
122. C.C. Wykoff, C. Sotiriou, M.E. Cockman, P.J. Ratcliffe, P. Maxwell, and E. Liu Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene Br J Cancer 90 2004 1235 1243
123. Foy RL, Chitalia VC, Panschenko MV, Boletta A, Qian F, Tsoikas L, et al. Regulation of jade1 by the polycystins. In: American Society of Nephrology, Annual Meeting, J Am Soc Nephrol, St. Louis, Missouri, 2004; P0689.